I'm not sure quarter to quarter revenue comparisons are at all meaningful, but the stock is down a dime.
7:39AM Ariad Pharm misses by $0.06, misses on revs (ARIA) 3.71 : Reports Q3 (Sep) loss of $0.18 per share, $0.06 worse than the Thomson Reuters consensus of ($0.12); revenues fell 42.6% year/year to $1.2 mln vs the $1.4 mln consensus. The co expects to end 2010 with cash provided by operations of ~$5 million, reflecting the impact of payments received in connection with executing the restructured agreement with Merck in May 2010. With the net proceeds from the October offering of common stock, the co expects that its cash and cash equivalents at December 31, 2010 will be ~$102 million.
